연혁 1 페이지

LoginI Join us Ko

COMPANY

Cartilage defect disease Global No.1 ATEMs

COMPANY

Cartilage defect disease Global No.1 ATEMs

History

We become the world's first tissue
regeneration treatment company.

History

Development
History

Nov, 2021

Selected as the Ministry of SMEs and Startups. project

Oct, 2021

Selected as the regenerative medical technology development’ government project

Sept, 2021

Selected as the 2021 excellent venture company (by Venture Business Association)

Aug, 2021

Changed to be managed by the two CEO system- Park Sang-hyug and Min Byoung-hyun

May, 2020

GMP production: Regenerative therapy product (Seoul), Medical device(Deajeon) secured

Nov, 2019

Relocation of Head Office(Munjeong-dong, Songpa-gu, Seoul)
Selected as a project by Ministry of Healthy and Welfares

Aug, 2019

Series A investment from HansbioMed Co., Ltd.

Jun, 2018

Selected as a project by TIPS / Korea Institute of Marine Science & Technology
Promotion / Ministry of Health and Welfare
Certified as Venture Company(Korean Venture Capital Association)

May, 2018

Completion of transfer of 6 key patents/ 14 exclusive license contracts.

Apr, 2018

Joint technology development agreement with Brilliant Research Pte. Ltd.
Establishment of a corporate-affiliated research institute.

Jan, 2018

Foundation of ATEMs Co., Ltd. in Kwanggyo, Suwon

2021

4 patents granted in Korea and Japan (in 2015-2021)
IND submission for A-paste-C phase 1/2 clinical trial

2017

Completion of non-clinical trial of incurable disease treatments based on
source cells and source materials

2004

Development of cell therapy product-based technology
/ Approval of ArtiCell (cell therapy product) product

1996

First autologous chondrocyte implantation procedure in Korea
(the second ACI procedure in the world)
Ajou University Medical Center, Cell Therapy Center

History

We become the world's first tissue
regeneration treatment company.

History

Nov, 2021

Selected as the Ministry of SMEs and Startups. project

Oct, 2021

Selected as the regenerative medical technology development’
government project

Sept, 2021

Selected as the 2021 excellent venture company
(by Venture Business Association)

Aug, 2021

Changed to be managed by the two CEO system-
Park Sang-hyug and Min Byoung-hyun

May, 2020

GMP production: Regenerative therapy product (Seoul),
Medical device(Deajeon) secured

Nov, 2019

Relocation of Head Office(Munjeong-dong, Songpa-gu, Seoul)
Selected as a project by Ministry of Healthy and Welfares

Aug, 2019

Series A investment from HansbioMed Co., Ltd.

Jun, 2018

Selected as a project by TIPS / Korea Institute of Marine Science
& Technology Promotion / Ministry of Health and Welfare Certified
as Venture Company (Korean Venture Capital Association)

May, 2018

Completion of transfer of 6 key patents/ 14 exclusive license contracts.

Apr, 2018

Joint technology development agreement with Brilliant Research
Pte. Ltd. Establishment of a corporate-affiliated research institute.

Jun, 2018

Foundation of ATEMs Co., Ltd. in Kwanggyo, Suwon

Development
History

2021

4 patents granted in Korea and Japan (in 2015-2021)
IND submission for A-paste-C phase 1/2 clinical trial

2017

Completion of non-clinical trial of incurable disease treatments
based on source cells and source materials

2004

Development of cell therapy product-based technology
/ Approval of ArtiCell (cell therapy product) product

1996

First autologous chondrocyte implantation procedure in Korea
(the second ACI procedure in the world)
Ajou University Medical Center, Cell Therapy Center